Mesoblast Limited has released a press release.
LVAD Trial Results Provide Potential Regulatory Pathway
Filed with ASX ·
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
In the deck
Story so far
Earlier from Mesoblast
- MSB Expands Partnership With JCR For Skin Disease
- Completion of Tasly Transaction, and Appendix 3B
- Day 180 Survival Outcomes In aGvHD Phase 3 Trial
- Tasly Receives Approvals For Transaction With MSB
- Mesoblast Reports on Annual and Fourth Quarter Results
Later from Mesoblast
- LVAD Results Webcast Presentation
- Response to ASX query
- P3 Trial of MSBs Cell Therapy in CHF Completes Recruitment
- MSB Draws US$15 Million From Existing Facility
- MSB Licensee Files For Skin Disease Marketing Approval
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast